NewAmsterdam Pharma appoints Adele Gulfo as independent director

NewAmsterdam Pharma Co N.V.

Adele Gulfo, former CEO of Sumitomo Pharma America's Biopharma Unit, joins Board effective April 15, 2025.
Granted options for 50,700 ordinary shares at $16.06/share, vesting over 3 years with 33% on first anniversary.
Granted 10,860 RSUs vesting in equal thirds over three years from April 15, 2025.
Gulfo led launches of Lipitor and Crestor; oversaw $12B+ revenue at Pfizer's U.S. primary care unit.
Appointment adds commercial expertise as company prepares for potential obicetrapib launch in 2026.

item 5.02 item 7.01 item 9.01

Executive movements

Machine-extracted from this filing. Every card cites the SEC source. See all recent executive movements.

Appointed

Adele Gulfo

Director

NAMS · NewAmsterdam Pharma Co N.V.

Effective: 2025-04-15
Filed: April 17, 2025, 7:59 PM ET

On April 15, 2025, the board of directors (the “Board”) of NewAmsterdam Pharma Company N.V. (the “Company”) appointed Adele Gulfo to serve as a member of the Board.

Key facts

Extracted from this filing and checked against the source text.

Executive change SEC 8-K Item 5.02 confidence 0.95

Adele Gulfo was appointed as Director at NewAmsterdam Pharma Co N.V..

Action: appointed
Role: Director

Exact text from the filing

On April 15, 2025, the board of directors (the “Board”) of NewAmsterdam Pharma Company N.V. (the “Company”) appointed Adele Gulfo to serve as a member of the Board.

View on SEC.gov

NewAmsterdam Pharma Co N.V. filing history →

Source: SEC EDGAR

accession 0001193125-25-084428

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.